Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Griesinger

Showing results (21-30 of 159) with videos related to

Pageof 16
Sort By:
Molecular Cancer|January 29, 2010
The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemiaJasmin R Agarwal, Frank Griesinger, Walter Stühmer, et al.
Journal of Cancer Research and Clinical Oncology|July 6, 2014
Superior vena cava syndrome caused by a malignant tumor: a retrospective single-center analysis of 124 casesKarin Hohloch, Nick Bertram, Lorenz Trümper, et al.
Lung Cancer (Amsterdam, Netherlands)|April 16, 2004
Secondary leukaemia after cure for locally advanced NSCLC: alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIBFrank Griesinger, Michael Metz, Lorenz Trümper, et al.
Onkologie|September 16, 2006
[Surgery and adjuvant therapy in non-small-cell lung carcinoma (NSCLC). (stage I through operable stage IIIA)]Wilfried Eberhardt, Rainer Fietkau, Frank Griesinger, et al.
Journal of Comparative Effectiveness Research|February 25, 2022
Health technology assessments and real-world evidence: tell us what you want, what you really, really wantFrank Griesinger, Oliver Cox, Cormac Sammon, et al.
International Journal of Environmental Research and Public Health|August 12, 2022
Needs of Lung Cancer Patients Receiving Immunotherapy and Acceptance of Digital and Sensor-Based Scenarios for Monitoring Symptoms at Home-A Qualitative-Explorative StudyMilena von Kutzleben, Jan Christoph Galuska, Andreas Hein, et al.
Haematologica|September 2, 2011
Managing individuals with propensity to myeloid malignancies due to germline RUNX1 deficiencyTim Ripperger, Marcel Tauscher, Detlef Haase, et al.
Journal of Cancer Research and Clinical Oncology|May 9, 2022
Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approachFabienne Englmeier, Annalen Bleckmann, Wolfgang Brückl, et al.
Journal of Cancer Research and Clinical Oncology|March 10, 2012
Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I studyMirko Nitsche, Hans Christiansen, Katinka Lederer, et al.
Oncotarget|November 13, 2018
Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithmsFrank Griesinger, Julia Roeper, Christoph Pöttgen, et al.
Pageof 16

Showing results (21-30 of 159) with videos related to

Sort By:
Pageof 16
Molecular Cancer|January 29, 2010
The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemiaJasmin R Agarwal, Frank Griesinger, Walter Stühmer, et al.
Journal of Cancer Research and Clinical Oncology|July 6, 2014
Superior vena cava syndrome caused by a malignant tumor: a retrospective single-center analysis of 124 casesKarin Hohloch, Nick Bertram, Lorenz Trümper, et al.
Lung Cancer (Amsterdam, Netherlands)|April 16, 2004
Secondary leukaemia after cure for locally advanced NSCLC: alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIBFrank Griesinger, Michael Metz, Lorenz Trümper, et al.
Onkologie|September 16, 2006
[Surgery and adjuvant therapy in non-small-cell lung carcinoma (NSCLC). (stage I through operable stage IIIA)]Wilfried Eberhardt, Rainer Fietkau, Frank Griesinger, et al.
Journal of Comparative Effectiveness Research|February 25, 2022
Health technology assessments and real-world evidence: tell us what you want, what you really, really wantFrank Griesinger, Oliver Cox, Cormac Sammon, et al.
International Journal of Environmental Research and Public Health|August 12, 2022
Needs of Lung Cancer Patients Receiving Immunotherapy and Acceptance of Digital and Sensor-Based Scenarios for Monitoring Symptoms at Home-A Qualitative-Explorative StudyMilena von Kutzleben, Jan Christoph Galuska, Andreas Hein, et al.
Haematologica|September 2, 2011
Managing individuals with propensity to myeloid malignancies due to germline RUNX1 deficiencyTim Ripperger, Marcel Tauscher, Detlef Haase, et al.
Journal of Cancer Research and Clinical Oncology|May 9, 2022
Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approachFabienne Englmeier, Annalen Bleckmann, Wolfgang Brückl, et al.
Journal of Cancer Research and Clinical Oncology|March 10, 2012
Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I studyMirko Nitsche, Hans Christiansen, Katinka Lederer, et al.
Oncotarget|November 13, 2018
Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithmsFrank Griesinger, Julia Roeper, Christoph Pöttgen, et al.
Pageof 16